150 results about "Lidocaine Hydrochloride" patented technology

Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal.

The invention discloses gel for treating herpes zoster. The gel is prepared from the following raw materials in percentage by weight: 2-4 percent of acyclovir, 1-3 percent of lidocaine hydrochloride, 0.05-0.15 percent of tacrolimus, 0.04-0.06 percent of vitamin B12, 0.5-1.5 percent of a gel substrate, 1-1.5 percent of a neutralizer, 4-6 percent of a moisturizer, 25-35 percent of a solvent, 1-3 percent of a solubilizer, 0.5-1.5 percent of an absorption enhancer and the balance of water. The gel substrate is any one or more of carbopol 940, hydroxypropyl methyl cellulose, alginate, gelatin or starch; the neutralizer is triethanolamine or sodium hydroxide; the moisturizer is glycerin; the solvent is ethyl alcohol; the solubilizer is tween-80; the absorption enhancer is laurocapram. The invention also discloses a preparation method of the gel. All medicine components in the gel have a synergistic effect, the dosage of the medicines can be reduced, and the adverse reaction of the medicines is reduced.

Therapeutic compositions, particularly sprayable aqueous compositions, comprise ketorolac or a pharmaceutically acceptable salt, in combination with a local anesthetic, such as lidocaine hydrochloride. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation and have the benefit of reduced stinging and improved efficacy, compared to known nasally administered compositions.

The invention relates to bleeding-stopping, inflammation-diminishing and pain-relieving nano emulsion for use in minimally invasive beauty treatment therapy and a preparation method thereof. The nano emulsion is prepared from the following raw materials in part by weight: 0.0055 part of thrombase freeze-dried powder, 0.0005 part of epinephrine, 5 parts of calcium chloride, 1 part of sodium chloride, 6 parts of coix seed essence oil, 6 parts of as arum volatile oil, 5 parts of lidocaine hydrochloride, 13.6 parts of isopropyl myristate, 27.6 parts of octoic acid and capric acid polyethylene glycol glyceride, 9.2 parts of polyglycerol-3-dioleate and 26.594 parts of distilled water. The nano emulsion has diversified functions and has bleeding-stopping, inflammation-diminishing and pain-relieving effects, so the complex process of the minimally invasive beauty treatment therapy is simplified. In addition, a nano transdermal technique is adopted to promote the functional components to enterskin effectively, constantly and controllably to produce the bleeding-stopping, inflammation-diminishing and pain-relieving effects; and the toxic and side effects of the nano emulsion can be reducedgreatly.

The invention relates to a chitosan hemostatic and pain-relieving powder and a preparation method thereof. The chitosan hemostatic and pain-relieving powder is prepared by mixing carboxymethyl chitosan, sodium alginate, thrombin and lidocaine hydrochloride. The ratio is: 0.1-10 parts of carboxymethyl chitosan, 0.1-10 parts of sodium alginate, 0.0004 parts of thrombin, 0.1-2 parts of lidocaine hydrochloride, cross-linked with calcium chloride, washed, dried, and ground into powder , has the advantages of simple and green preparation method, low production cost, high water absorption swelling rate, convenient use, and good hemostatic and analgesic effects.

The invention relates to a preparation method of a lidocaine hydrochloride impurity E, and belongs to the technical field of compound synthesis processes. The preparation method of the lidocaine hydrochloride impurity E comprises the following steps that: 4-morpholine-3-aniline is dissolved in a solvent; then an obtained solution reacts with substituted 2, 6-dimethylphenyl acetamide under the action of an acid-binding agent to generate the lidocaine hydrochloride impurity E. The lidocaine hydrochloride impurity E with higher purity can be obtained, the yield of the lidocaine hydrochloride impurity E is higher, and the purification steps are fewer.